Dysthymic Disorder With Depressive Episodes Therapeutics
1. Barhemsys patent expiration
Treatment: Treatment of post-operative nausea and vomiting; Prevention and treatment of post-operative nausea and vomiting; Prevention of post-operative nausea and vomiting
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12005042 | LXO | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(11 years from now) | |
| US11357753 | LXO | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(11 years from now) | |
| US10525033 | LXO | Use of amisulpride as an anti-emetic |
Mar, 2031
(4 years from now) | |
| US9084765 | LXO | Use of amisulpride as an anti-emetic |
Feb, 2034
(7 years from now) | |
| US9889118 | LXO | Use of amisulpride as an anti-emetic |
Mar, 2031
(4 years from now) | |
| US9545426 | LXO | Use of amisulpride as an anti-emetic |
Mar, 2031
(4 years from now) | |
| US12194022 | LXO | Use of amisulpride as an anti-emetic |
Mar, 2031
(4 years from now) | |
| US12329740 | LXO | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 27 February, 2024
Market Authorisation Date: 26 February, 2020
Dosage: SOLUTION
More Information on Dosage
BARHEMSYS family patents
